Navigation Links
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Date:12/2/2007

l marketing approval."

Mylan licensed the U.S. and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. (currently Johnson & Johnson Pharmaceutical Research and Development) in 2001. Nebivolol is already registered and successfully marketed in more than 50 other countries outside of North America for the treatment of hypertension.

Forest licensed nebivolol from Mylan in January 2006 and has responsibility for all sales and marketing as well as current and future development programs. Mylan has retained an option to co-promote the product in the future.

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, Benicar HCT(R)* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, and AZOR(TM)* (amlodipine and olmesartan medoxomil) a calcium channel blocker and angiotensin receptor blocker combination product, all indicated for the treatment of hypertension.

*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and
'/>"/>

SOURCE Mylan Inc.; Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
2. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. American Red Cross Issues Blood Supply Alert
5. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
6. New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
7. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
8. Audio: New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
9. Dallas-Area Transplant Meeting Puts Spotlight on Key Issues
10. Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America
11. California State PTA Issues Statement Regarding Presidents Veto of SCHIP Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Regents Health Resources, a consulting firm ... health care industry veteran Daryl Demonbreun and former St. ... the company’s ambitious plans to grow into a full-service ... moving along at a steady pace for nearly 20 ... notch,” says Bob Maier, founder and chief executive officer ...
(Date:7/29/2014)... Test instruments after processing to assure ... where it matters most – on the surgical ... premium domestic appliances, introduces ProCare Protein Check, a ... cleaned. The ProCare liquid is applied directly to ... After 3 minutes, users visually determine the presence ...
(Date:7/29/2014)... rates rise in association with extremely hot weather. The ... 2003, for example, resulted in about 22,000 extra deaths. ... at the Institute of Epidemiology II at the Helmholtz ... the number of deaths caused by cardiovascular disease in ... temperatures in the study. , "Our findings confirm the ...
(Date:7/29/2014)... Healthcare staffing agency Medical Solutions ... Tomorrow Scholarship Competition winners:, ,     Alonso ...     Racheal D., Freshman, Cerritos College in Norwalk, ... College in Houston, TX , Each ... hosts the Nurses of Tomorrow Scholarship competition as ...
(Date:7/29/2014)... 2014 Gummy smile surgeon , Dr. ... gums treatments that can enhance and perfect gummy smiles and ... that displays the teeth to their best advantage. Some smiles ... have gums that are dark or discolored. Patients with these ... about their smiles or experience a high level of smile ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Mortality rates increase due to extreme heat and cold 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Gummy Smile Surgeon, Dr. Alex Farnoosh, Now Offers Procedures to Improve Gummy Smiles and Dark Gums 2
... ... Stroke and High Resolution, WATERTOWN, Mass., Sept. ... deformable mirror (DM),products for adaptive optics (AO) systems, today announced ... of the most innovative products,of 2007. In their annual Micro/Nano ...
... Challenge and AstraZeneca Join Forces to Promote Healthy ... Eating and Physical Activity, ... a new educational campaign will teach children ages,6-12 healthy habits both ... and AstraZeneca, "Habits for Health" will provide,250 schools, as well as ...
... N.Y., Sept. 10 Physicians and patients,of ... benefit from an,enhanced partnership between Physicians Practice ... more than 7,000 physicians in Brooklyn,and Staten ... thereby,improving patient care. (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/NETU093LOGO ...
... RELEASE , PCBs may threaten killer whale populations ... Orcas or killer whales may continue to suffer the ... next 30 60 years, despite 1970s-era regulations that ... in Canada report. Their study, which calls for better ...
... Just 13% of ,positive, phase II studies go forward despite ... than one in eight phase II cancer clinical trials with ... that,s needed to bring a new therapy to patients, a ... conducting the phase II effort knew beforehand that, due to ...
... Longstanding Tradition of Innovation in ... Leading Technology Provider, SILVER SPRING, Md. and ... the Center for Medical Simulation (CMS) today,announced that ... for the facility,s already cutting edge simulation programs.,B-Line ...
Cached Medicine News:Health News:Boston Micromachines Multi-DM Named One of the Year's Most Innovative Products 2Health News:Boston Micromachines Multi-DM Named One of the Year's Most Innovative Products 3Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 2Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 3Health News:Back-to-School Campaign Motivates Children and Parents to Embrace 'Habits for Health' 4Health News:Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors 2Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 2Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 3Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 4Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 5Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 6Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 7Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 8Health News:American Chemical Society's Weekly Presspac -- Sept. 5, 2007 9Health News:Study Questions Dead-End Cancer Clinical Trials 2Health News:Study Questions Dead-End Cancer Clinical Trials 3Health News:Study Questions Dead-End Cancer Clinical Trials 4Health News:Study Questions Dead-End Cancer Clinical Trials 5Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 2Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 3
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
(Date:7/28/2014)... FRANCISCO , July 28, 2014  Dignity ... it has received the Get With The Guidelines®-Stroke ... improvement measures outlined by the American Heart Association/American ... Stroke is the number four cause of death ... the United States , according ...
(Date:7/28/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye has rescheduled ... call with investors to July 31, 2014 at 5:00 ... the release date and conference call to enable senior ... Watanabe , President of STAAR Japan, who passed away ...
Breaking Medicine Technology:EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... , SAN DIEGO , Jan. 20, 2010 ... Quarterly Update Conference Call for the fourth quarter and full year 2009 ... / 2:00 p.m. PT . Daniel M. Bradbury , Amylin,s president ... post-market, Amylin will release financial results for the fourth quarter and year ...
... , PLEASANTON, Calif. , ... ), a world leader in device-based mechanical circulatory support therapies ... it has received FDA approval of its PMA (Pre-Market Approval) ... Ventricular Assist System) for Destination Therapy (DT).   , With ...
Cached Medicine Technology:Amylin Pharmaceuticals to Webcast Year-End Financial Results 2Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy 2Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy 3Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy 4Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy 5Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy 6
... Used to dilate the lower ... to assess possible submucosal tunneling. ... topical anesthetic in the ureter. ... by, or dislodgment of a ...
Used for drainage and retrograde pyelogram. The spiral tip aids in negotiation of a tortuous or partially obstructed ureter. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: